Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de Lalla, F.
Right arrow Articles by Lazzarini, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Lalla, F.
Right arrow Articles by Lazzarini, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 843-846
© 2000 The British Society for Antimicrobial Chemotherapy

Brief report

Safety and efficacy of recombinant granulocyte colony-stimulating factor as an adjunctive therapy for Streptococcus pneumoniae meningitis in non-neutropenic adult patients: a pilot study

Fausto de Lalla*, Roberto Nicolin and Luca Lazzarini

Department of Infectious Diseases, S. Bortolo Hospital, via Rodolfi, 36100 Vicenza, Italy

Twenty-two non-neutropenic adult patients with Streptococcus pneumoniae meningitis received granulocyte-colony stimulating factor (G-CSF) (300–450 Ìg/day subcutaneously for 6 days) in addition to cefotaxime plus dexamethasone (9–12 g/day for 10 days and 16 mg/day for 3 days iv, respectively). Patients recovered without evident sequelae in all cases but one (with bilateral hearing deficit). No adverse event was recorded. Improvement of inflammation indices in the cerebrospinal fluid was rapid. The most rapid improvement was seen in glucose concentration, which returned to normal ranges within 24–48 h of treatment. In this study G-CSF administration appeared to be safe and effective; further controlled clinical trials are justified.

* Corresponding author. Tel: +39-0444-993998; Fax: +39-0444-993616; E-mail: fdl.vi{at}gpnet.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
M. Cruciani, B. A. Lipsky, C. Mengoli, and F. de Lalla
Are Granulocyte Colony-Stimulating Factors Beneficial in Treating Diabetic Foot Infections?: A meta-analysis
Diabetes Care, February 1, 2005; 28(2): 454 - 460.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.